C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 32,968 shares of the company's stock, valued at approximately $2,281,000.
Several other hedge funds also recently made changes to their positions in the company. Quent Capital LLC lifted its stake in shares of Henry Schein by 91.2% in the 4th quarter. Quent Capital LLC now owns 677 shares of the company's stock worth $47,000 after acquiring an additional 323 shares during the period. Equitable Trust Co. acquired a new position in Henry Schein during the fourth quarter worth about $417,000. Wingate Wealth Advisors Inc. purchased a new stake in shares of Henry Schein during the fourth quarter worth about $176,000. Savant Capital LLC grew its holdings in shares of Henry Schein by 43.9% during the fourth quarter. Savant Capital LLC now owns 4,651 shares of the company's stock worth $322,000 after buying an additional 1,420 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Henry Schein by 3.8% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,491 shares of the company's stock worth $934,000 after buying an additional 497 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on the stock. Mizuho assumed coverage on shares of Henry Schein in a report on Wednesday, December 4th. They issued a "neutral" rating and a $75.00 target price for the company. StockNews.com upgraded shares of Henry Schein from a "sell" rating to a "hold" rating in a report on Thursday, November 7th. Jefferies Financial Group boosted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Barrington Research boosted their target price on shares of Henry Schein from $82.00 to $90.00 and gave the company an "outperform" rating in a report on Thursday, January 30th. Finally, Bank of America raised shares of Henry Schein from an "underperform" rating to a "buy" rating and lifted their price target for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $80.09.
Read Our Latest Stock Report on Henry Schein
Henry Schein Stock Down 2.1 %
HSIC traded down $1.62 during trading on Friday, hitting $76.00. The company had a trading volume of 1,455,207 shares, compared to its average volume of 1,474,978. The company has a market cap of $9.48 billion, a PE ratio of 31.28, a P/E/G ratio of 2.21 and a beta of 0.91. The business has a 50-day moving average of $74.01 and a 200-day moving average of $72.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63.
Insider Activity at Henry Schein
In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares in the company, valued at $6,577,950. The trade was a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.14% of the stock is currently owned by corporate insiders.
Henry Schein Company Profile
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.